17. Estimated life expectancy of at least 5 years irrespective of the diagnosis of breast cancer. 18. The patient must be accessible for scheduled visits, treatment and follow-up. 19. Normal cardiac function after neoadjuvant chemotherapy must be confirmed according to local guidelines. Results for...
Addition of the antiangiogenic agent bevacizumab to paclitaxel significantly improves response rates and progression-free survival for metastatic breast cancer (MBC). To assess the activity of docetaxel plus bevacizumab, a multicenter phase II trial was conducted. Patients and Methods Patients with measura...
The median age for breast cancer diagnosis is 62years, but adisproportionate number of patients are over the age of 75years and the majority of those have hormone receptor-positive, human epidermal growth factor receptor-2 (HER2)-negative cancers. This review provides a logical algorithm to ...